Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPATE vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Social anxiety disorder,Obsessive-compulsive disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
50 mg orally once daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
95-98% bound, primarily to albumin and alpha-1-acid glycoprotein.
~10-20% bound to plasma proteins (primarily albumin).
0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution).
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%).
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No dosage adjustment required for GFR ≥30 m L/min; GFR <30 m L/min: not recommended.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not approved for pediatric use.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
No dosage adjustment required; monitor renal function.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Suicidality risk in pediatric/young adult patients,Serotonin syndrome risk with concomitant serotonergic drugs,Bleeding risk with anticoagulants/antiplatelets,Activation of mania/hypomania,Seizure risk in patients with epilepsy,Angle-closure glaucoma risk,Hyponatremia risk in elderly/dehydrated patients,Discontinuation syndrome with abrupt cessation
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Concurrent MAOIs (including linezolid and methylene blue),Concurrent pimozide,Known hypersensitivity to sertraline
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption.,Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy.,St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Due to significant pharmacokinetic changes in pregnancy, including increased clearance (by 50%) and expanded volume of distribution, the dose of SERPATE should be increased by 30% during the second and third trimesters. Monitor therapeutic drug levels to maintain trough concentrations within the target range. Postpartum, reduce to prepregnancy dose within 48 hours to avoid toxicity.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take sertraline exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor.,Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time.,Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds).,Avoid alcohol, as it can worsen side effects and reduce drug effectiveness.,Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPATE vs ALDOMET, answered by our medical review team.
SERPATE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPATE and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPATE is: 50 mg orally once daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPATE and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPATE is classified as Category C. SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second . ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.